Review
Open Access
Advances in the management of pancreatic ductal adenocarcinoma
Grainne M. O’Kane, Farah Ladak and Steven Gallinger
CMAJ June 07, 2021 193 (23) E844-E851; DOI: https://doi.org/10.1503/cmaj.201450
Grainne M. O’Kane
Princess Margaret Cancer Centre (O’Kane, Gallinger), University Health Network, Toronto, Toronto, Ont.; University of Alberta (Ladak), Edmonton, Alta.
MB BCh BAO MDFarah Ladak
Princess Margaret Cancer Centre (O’Kane, Gallinger), University Health Network, Toronto, Toronto, Ont.; University of Alberta (Ladak), Edmonton, Alta.
MD MPHSteven Gallinger
Princess Margaret Cancer Centre (O’Kane, Gallinger), University Health Network, Toronto, Toronto, Ont.; University of Alberta (Ladak), Edmonton, Alta.
MD MScRelated Articles
- O’Kane, G. M., Ladak, F., & Gallinger, S. (2021). Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique. CMAJ, 193(34), E1362-E1370. Accessed May 09, 2024. https://doi.org/10.1503/cmaj.201450-f.
In this issue
Article tools
Respond to this article
Advances in the management of pancreatic ductal adenocarcinoma
Grainne M. O’Kane, Farah Ladak, Steven Gallinger
CMAJ Jun 2021, 193 (23) E844-E851; DOI: 10.1503/cmaj.201450
Jump to section
- Article
- Who is at risk for pancreatic ductal adenocarcinoma?
- How is pancreatic ductal adenocarcinoma diagnosed and staged?
- What are the treatment options for patients with operable disease?
- How should patients with locally advanced disease be managed?
- What progress has been made in the treatment of metastatic disease?
- What are emerging targeted treatments for PDAC?
- Conclusion
- Footnotes
- References
- Figures & Tables
- Responses
- Metrics